Julie Enevold Brooker discusses what she sees as Janssen’s responsibility to help improve the Danish healthcare system beyond just bringing innovative medicines to patients, gives her thoughts on the new Danish National Life Science Strategy, and outlines how Danish patients could have even better access to innovation.
All stakeholders want to maintain our leading position on access, which will perhaps require even closer collaboration with the Medicines Council and Amgros, making sure that we understand each other and have full clarity
